Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Panobinostat |
| Synonyms | |
| Therapy Description |
Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Panobinostat | Farydak | LBH589 | HDAC Inhibitor 38 | Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | colon cancer | not applicable | Panobinostat | Preclinical | Actionable | In a preclinial study, Faridak (panobinostat) enhanced the cytotoxicity of TRAIL, tumor necrosis factor-related apoptosis-inducing ligand, in colon cancer cell lines (PMID: 21965751). | 21965751 |
| Unknown unknown | rhabdoid cancer | not applicable | Panobinostat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Farydak (panobinostat) treatment of rhabdoid cancer cell lines in culture resulted in cell cycle arrest and cell differentiation and in cell line xenograft models, inhibition of tumor growth and a decrease in tumor size (PMID: 26920892). | 26920892 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02032810 | Phase I | Panobinostat Ipilimumab | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | Active, not recruiting | USA | 0 |
| NCT01321346 | Phase I | Cytarabine Panobinostat | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | Completed | USA | 0 |
| NCT01169636 | Phase Ib/II | Panobinostat Pegfilgrastim Carboplatin + Etoposide + Ifosfamide | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | Completed | USA | 0 |
| NCT00946647 | Phase II | Panobinostat Azacitidine | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | Completed | USA | CAN | 12 |
| NCT04804709 | Phase I | Panobinostat | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | Not yet recruiting | USA | 0 |
| NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Recruiting | USA | 0 |
| NCT01336842 | Phase I | Cisplatin Panobinostat Pemetrexed Disodium | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Completed | USA | 0 |
| NCT01032148 | Phase I | Panobinostat | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
| NCT02506959 | Phase II | Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma | Recruiting | USA | 0 |
| NCT02717455 | Phase I | Panobinostat | Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma | Recruiting | USA | 0 |
| NCT02720510 | Phase II | Panobinostat Bortezomib + Dexamethasone + Lenalidomide | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) | Terminated | USA | 0 |
| NCT02722941 | Phase II | Panobinostat | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | Active, not recruiting | USA | 0 |
CKB BOOST